Study on the Effectiveness of EGb 761® Vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis

• Evolution of the following tests between baseline and week 24:
• Multiple Sclerosis Functional Composite Test
• Selective Reminding Test
• 10/36 Visual-Spatial Recall Test
• Symbol Digit Modalities Test
• Trail Making Test A and B
• Verbal Fluency Test
• Empan Test
• Evolution of the following scales between baseline and week 24:
• Cognitive Deficit Interview based screen
• Anxiety Brief Scale
• Beck Depression Inventory Scale
• Modified Fatigue Impact Scale
• Evolution of Quality of Life
• Evolution of the following between baseline, week 12, and week 24: Kurtzke Extended Disability Status Scale, and Clinician Interview Based Impression of Change

The purpose of this study is to determine whether the use of EGb 761 by patients with Relapsing-Remitting Multiple Sclerosis is effective in improving cognition, when compared to placebo.

Inclusion Criteria:

• Patient with Multiple Sclerosis Relapsing-Remitting form
• Patient with cognitive impairment (as spontaneous complaint by either patient or family)
• Patient treated with interferon and maintaining same dosage for previous 6 months
• Patient without major disability (Kurtzke Extended Disability Status Scale ≤6)

Exclusion Criteria:

• Clinical Multiple Sclerosis relapse within 3 months prior to participation
• Major psychiatric disease according to Diagnostic and Statistical Manual of Mental Disorders, 4th Ed.
• Other concomitant disorders possibly jeopardizing the cognitive status evaluation or the follow up of the patient (severe impairment of visual or motor function which may prevent participation in neuropsychological testing)